pHyph
pHyph is being developed as a local treatment that is expected to cure bacterial vaginosis and prevent recurrence.
pHyph
pHyph is being developed as a local treatment that is expected to cure bacterial vaginosis and prevent recurrence.
A total of 82% of the subjects in a concluded trial were clinically cured of bacterial vaginosis after seven days
pHyph has demonstrated efficacy and safety results that other treatments have so far been unable to surpass
pHyph has been shown to have an excellent medical effect. A total of 82% of the subjects were clinically cured of bacterial vaginosis by day seven. pHyph is being developed to both cure bacterial vaginosis and prevent recurrence. The vaginal tablet is so safe to use that it will be possible for the treatment to be sold over the counter, and it is expected to be an easily accessible treatment option when an infection occurs.
Data on file.
- Restores the pH to its natural level
- Restricts the growth of infectious bacteria
- Restores the vaginal bacterial flora and thereby reduces the risk of recurrent bacterial vaginosis
In cases of bacterial vaginosis, the normal pH of the vagina is increased and an imbalance occurs in the bacterial flora.
The infectious bacteria begin to thrive under a type of membrane called a biofilm.
pHyph is a vaginal tablet that lowers the pH to its natural level (4.5) and restores the healthy vaginal bacterial flora, thereby reducing the risk of recurrent bacterial vaginosis.
The active substance in pHyph is GDA 001. This substance has always been part of our environment and is well documented. GDA 001 has GRAS status* and is used as an approved food additive.
*Generally Regarded As Safe (FDA)
